Posted on 6/28/17
Dr. Luis Zapiach & Dr. John Cozzone Named "Top Doctors" in Plastic Surgery by Castle Connolly
From surgical procedures such breast augmentation and blepharoplasty to non-surgical treatments like Ultherapy® and dermal fillers, Dr. Luis Zapiach and Dr. John Cozzone strive to provide . . .
Posted on 6/27/17
Robin S. Plumer Joins Samaritan Healthcare & Hospice as Hospice and Palliative Care Physician
Robin S. Plumer, DO, of Cherry Hill, New Jersey, has joined Samaritan Healthcare & Hospice as a
Posted on 6/27/17
Pfizer: Negative Signs?
Pfizer Inc. (PFE) is a leading producer of pharmaceutical products. While the industry is believed to be on the rise, the company reported a decline in . . .
Posted on 6/27/17
Teva: A Great Investment Opportunity
Teva Pharmaceutical Industries (TEVA) has seen its shares under pressure for quite some time now. A lot of investors seem quite concerned about the company’s current . . .
Posted on 6/27/17
Better Buy: Merck & Co. Inc. vs. AbbVie Inc.
Similarities between Merck & Co. Inc. (NYSE:MRK) and AbbVie Inc. (NYSE:ABBV) are easy to find. Both are big pharma companies with promising cancer drugs on the . . .
Posted on 6/27/17
Better Buy: Comcast Corporation vs. Charter Communications
As two of the top U.S. cable providers, Comcast (NASDAQ:CMCSA) and Charter Communications (NASDAQ:CHTR) each sit at the intersection of several big-ticket trends shaping the media, . . .
Posted on 6/26/17
Skipta and Continuum Clinical Partner to Launch the Center for Observational Research
LANCASTER, Pa. & NORTHBROOK, Ill.--(BUSINESS WIRE)--Continuum Clinical and Skipta are proud to announce the launch of the Center for Observational Research, connecting physicians and available “real . . .
Posted on 6/26/17
AmeriHealth New Jersey Welcomes AtlantiCare to Tier 1 in Its AmeriHealth Advantage Suite of Products
CRANBURY, N.J.--(BUSINESS WIRE)--AmeriHealth New Jersey today announced that AtlantiCare will be a Tier 1 provider in its AmeriHealth Advantage suite of products effective July 1, 2017. . . .
Posted on 6/26/17
Johnson & Johnson: The Better Activist Investor Bet
Johnson & Johnson (JNJ) has been quietly crushing its major peer in terms of stock performance - Procter & Gamble (PG), which has an activist investor. . . .
Posted on 6/26/17
3 Biotech Stocks for Enterprising Investors
Biotech stocks are a natural area of exploration for aggressive investors with high expectations for their stocks. After all, this high-growth industry is chock-full of novel . . .
Posted on 6/26/17
GlaxoSmithKline: 3 Reasons You Should Be Concerned
With a 4.56% annual dividend yield, GlaxoSmithKline (NYSE:GSK) is widely held by many dividend oriented investors. GSK is actually coming off an excellent Q1 2017, which . . .
Posted on 6/26/17
3 Reasons to Buy Celgene Stock and Never Sell
Celgene (NASDAQ:CELG) stock has been in my investment portfolio since 2013. I enjoyed a couple of great years with the biotech stock performing really well. Over . . .
Posted on 6/23/17
MTBC Announces $7.4 Million Public Offering
MTBC (NASDAQ: MTBC) (NASDAQ: MTBCP) a leading provider of proprietary, cloud-based electronic health records, practice management and mHealth solutions, today announced the pricing of a public . . .
Posted on 6/23/17
Celgene: I Don't Necessarily Understand The Science, But I Love The Numbers
IntroductionCelgene (NASDAQ:CELG) is a premier biotechnology company. It is a quintessential example of a pure growth stock. The company has strung together an incredibly consistent record . . .
Posted on 6/23/17
Why American Water Works Wouldn't Be a Warren Buffet Stock – but Should Be One of Yours!
Since Warren Buffett founded Berkshire Hathaway (NYSE:BRK-A) (NYSE:BRK-B) in 1965, the holding company's return has crushed the overall market. So, a cottage industry has been built . . .
Posted on 6/23/17
Rare Disease Report Forms Strategic Alliance Partnership with 31 Organizations
CRANBURY, N.J.--(BUSINESS WIRE)--Rare Disease Report®,the digital component of Rare Disease Communications®, is excited to welcome 31 organizations as part of the Strategic Alliance Partnership Program. Through . . .
Posted on 6/22/17
Celsion Corp. Announces Cancellation of Registered Direct Offering
LAWRENCEVILLE, N.J., June 22, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that it has cancelled the registered direct offering of common stock announced Monday, . . .
Posted on 6/22/17
Pfizer To Lose Exclusivity Of Key Brands
IntroductionPfizer (NYSE:PFE) recently took a market beating when it reported lower than expected revenue. Currently, it has recovered completely from that beating. Did the market overreact . . .
Posted on 6/21/17
Madrigal Pharmaceuticals Announces $35 Million Private Placement Offering
WEST CONSHOHOCKEN, Pa., June 21, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that it has entered into a definitive securities purchase agreement with . . .
Posted on 6/21/17
Interpace Diagnostics Closes $13.7 Million Public Offering
PARSIPPANY, N.J., June 21, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (Nasdaq:IDXG) a fully integrated commercial company that provides clinically useful molecular diagnostic tests and . . .
Posted on 6/21/17
Better Buy: Pfizer Inc. vs. AbbVie Inc.
When it comes to drugmaker dividends, Pfizer Inc. (NYSE:PFE) and AbbVie Inc.(NYSE:ABBV) stand out with higher-than-average yields. Of course, when shopping for pharmaceutical stocks, it pays . . .
Posted on 6/21/17
Citius Pharmaceuticals Announces US Patent Office Publication Of Enhanced Stability Patent Application
Citius Pharmaceuticals, Inc. (OTC BB: CTXRD), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today it has received notification . . .
Posted on 6/19/17
5 Reasons the Boring Parts of Johnson & Johnson's Business Should Generate Excitement
Johnson & Johnson's (NYSE:JNJ) consumer and medical device businesses weren't exactly called boring at the Goldman Sachs healthcare conference on Thursday. But they might as well . . .
Posted on 6/16/17
Teva: 3 Market Misreads
Aside from the now universally hated scandal-ridden basket case Valeant (NYSE:VRX), Teva Pharmaceuticals (NYSE:TEVA) is the worst performing large cap pharma stock since 2015. It has . . .
Posted on 6/15/17
Amicus Therapeutics: Is This Biotech an Orphan Underdog?
One of the hottest areas to invest in biotech is the "orphan" sector. Orphan diseases, as defined by the FDA, are medical conditions that affect fewer . . .

